MedPage Today -- TORONTO, April 16 -- Patients with the most common form of sight-threatening diabetic retinopathy get no benefit from calcium dobesilate, in clinical use since the 1980s, European researchers found.
MedPage Today -- TORONTO, April 16 -- Patients with the most common form of sight-threatening diabetic retinopathy get no benefit from calcium dobesilate, in clinical use since the 1980s, European researchers found.